The Maastricht Study

The Maastricht Study is an extensive phenotyping study that focuses on the etiology of type 2 diabetes, its classic complications (cardiovascular disease, nephropathy, neuropathy and retinopathy), and its emerging comorbidities, including cognitive decline, depression, and gastrointestinal, respiratory and musculoskeletal diseases. The study uses advanced state-of-the-art imaging techniques and extensive biobanking to determine health status in a population-based cohort of 10,000 individuals that is enriched with type 2 diabetes participants. The Maastricht Study is expected to become one of the most extensive phenotyping studies in both the general population and type 2 diabetes participants world-wide. A detailed description of the study design can be found in:

Eur J Epidemiol. 2014 Jun;29(6):439-51. doi: 10.1007/s10654-014-9889-0.

Key facts

Name of the connected EIT Health partner: MUMC+ and Maastricht University
Number of individuals: ~9000
Biobank confirmed willingness to provide samples/data for EIT Health studies: Potential collaborations will need a formal agreement from all parties involved.
Contact person(s) and contact data
(e-mail address, tel. no) for access purposes: +31 43 387 6600
Number of samples:
Sample type: Whole blood Buffy Coat Plasma Serum Cells Urine Faeces Hair DNA RNA
Website: see:

General information

Type of biobank: Oversampling for type 2 diabetes; Population
If longitudinal the frequency: Annual assessment of questionnaire data on morbidity. 2nd wave for all physical measurments is under construction, approximately 7 years later than wave 1.
Link to central portal to seek samples and data:
Broad consent: Yes
Option to recall donors: Yes
Option to recall family members: No

Biobank access procedure:

Major terms for access: See:
Ethical and legal compliance:
Speed and reliability of delivery:

Quality management system:

Compliance with international standards:
Current ISO certificates:


Clinical data linked to samples: Questionnaire data, Interview data, Imaging data, Clinical data, Phenotypic data, Genomics, Metabolomics, GWAS

see Biol Psychiatry. 2020 Mar 1;87(5):409-418. doi: 10.1016/j.biopsych.2019.08.016. Epub 2019 Aug 29.

Data standards:
Data security rules:

Biobank related service:

Research support, what type of expertise?: Expertise in epidemiology, diabetes and its complications, cardiovascular disease, cognitive decline and neuroimaging, depression, biomarker assessment
Core facility services; what type? Link?:
Queries from national health registers:
Links to the model contract and MTA:


IP rules, what is negotiable?:
Requirements to study results (access etc.):
Participant’s right to the information:
Number of access contracts with industry:

COVID-19 samples:

Access to biological samples from patients with COVID-19?

  • Serum
  • Full blood (for RNA extraction)
  • EDTA-Full blood (for DNA extraction)
  • EDTA-Plasma
  • Citrate-Plasma
  • PBMC (Peripheral Blood Mononuclear Cells)
  • Nasopharyngeal aspirate
  • Tracheal aspirate
Contact person(s) and contact data (e-mail address, tel. no) for access purposes